Local time

17 01 2019

Lithuania

Bulgaria

Romania

Czech Republic

Slovakia

Poland

Hungary

Croatia

CEE

Hot pharma & economy news

Print -

World pharma news

  • Merck, a leading science and technology company, today announced the ten startups that will be joining the seventh intake of its Accelerator program at the Merck Innovation Center in Darmstadt. The teams come from nine different countries, making 2019 the most international intake in the Merck Accelerator's history. They were chosen from a total of 565 applications, coming from startups based in 68 countries across the world.
    Merck welcomes ten new startups to its Innovation Center
  • People who sleep less than six hours a night may be at increased risk of cardiovascular disease compared with those who sleep between seven and eight hours, suggests a new study published in the Journal of the American College of Cardiology. Poor quality sleep increases the risk of atherosclerosis - plaque buildup in the arteries throughout the body - according to the study.
    Sleeping less than six hours a night may increase cardiovascular risk
  • AbbottAbbott (NYSE: ABT) announced today that it has exercised its option to purchase Cephea Valve Technologies, Inc., a privately held medical device company developing a less-invasive heart valve replacement technology for people with mitral valve disease. Financial terms were not disclosed. Abbott provided capital and secured an option to purchase Cephea in 2015.
    Abbott to acquire Cephea Valve Technologies, Inc.
  • Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE: BMY) announced that the European Commission has approved the combination of Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg ("low-dose") for the first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC).
    European Commission approves Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) for first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma
  • People with Duchenne muscular dystrophy (DMD) can develop an otherwise-rare muscle cancer, called rhabdomyosarcoma, due to the muscle cells' continuous work to rebuild the damaged tissue. However, little is known about how the cancer arises, hindering development of a treatment or test that could predict cancer risk.
    Muscle stem cells can drive cancer that arises in Duchenne muscular dystrophy

Pharmaceuticals News & Press Releases

McKinsey Quarterly

Pharma Marketing

  • Raises Price of Viagra<br /> <br /> Pfizer, the largest stand-alone pharmaceutical company in the US, raised the average wholesale price of 148 drugs by between 6 and 13.5 per cent, according to data, with a mean average increase of 8.8 per cent.
    Pfizer's "Dick" Move
  • Despite Hope in New Drugs<br /> <br /> According to the CDC, the average life expectancy at birth in the U.S. fell by 0.1 years, to 78.6, in 2016, following a similar drop in 2015. This is the first time in 50 years that life expectancy has fallen for two years running. In 25 other developed countries, life expectancy in 2015 averaged 81.8 years.
    Drop in U.S. Life Expectancy
  • Companies Leading the Way Implementing Disruptive Innovations<br /> <br /> This article features several examples of what the pharmaceutical industry is doing to implement disruptive digital innovations that help them manage clinical trials, improve their products, and support healthcare professionals and patients.
    The Pharma Digital Health Accelerator Club

Lithuania Economy

Latvia Economy

Estonia Economy

Czech Rep. Economy

Poland Economy

Slovakia Economy

Hungary Economy